ALT’s proprietary, fast-acting medical cannabis product is neutral in flavour, zero-calorie, sugar-free, vegan, keto, and paleo-friendly and are designed to allow for more effective delivery in comparison to other products such as tinctures and sprays.
Medical cannabis patients will reportedly benefit from a more rapid onset time of between 5-15 minutes and more efficient absorption. ALT’s water-compatible products are made using kinetically stabilised nanoemulsions which allow cannabinoids to be effectively absorbed by the body.
ALT offers precise dosing of cannabinoids, allowing patients and clinicians to tailor treatment based on individual needs and requirements for a range of health conditions.
“We are [honoured] to partner with GROW in bringing ALT’s completely differentiated brand and liquid medical cannabis technologies to the European medical markets,” said ALT CEO Robert Davis.
“After successfully launching ALT into California in December 2020, we are excited to expand internationally, our first step towards becoming a global brand. ALT’s mission is to Enhance Human Potential and we will do so, one patient at a time, through the power of our liquid cannabis platform.”
Through its new partnership with Grow Group Plc, ALT aims to have a range of EU GMP-certified medical cannabis products available to European patients through prescription by early 2022.
Grow GroupPlc CEO, Ben Langley stated: “Grow’s mission is to bring medical cannabis products to all patients who need them.
“We strive to constantly improve and innovate on our product offering. With our leading position and unique experience we are very confident that with ALT’s new mode of administration, using liquid medical cannabis, we are going to make another leap forward in providing patients with the best products and solutions for their symptom management.”
Grow Group Plc recently announced the launch of a crowdfunding campaign with Seedrs, seeking £3.2 million of investment from “socially conscious shareholders.”